CXCR-2 antagonists are of increasing importance as therapeutic agents for cancer and chronic inflammatory diseases [73,74], while ongoing clinical trials for CXCR-2 involve compounds such as ladarixin for diabetes 1 (NCT04628481), SX-682 for myelodysplastic syndromes (NCT04245397), metastatic pancreatic ductal adenocarcinoma (NCT04477343) and melanoma (NCT03161431) as well as autologous CXCR-2-modified CD70 CAR (8R-70CAR) T cells in GBM (NCT05353530). This evidence concerns the gene CD70 and cancer.